Pharmafile Logo
Pharmafocus logo
Advanced Search

arthritis

Showing 12 posts of 27 posts found.

bmss_orencia_was_recommended_in_draft_guidance

NICE recommends four treatments for arthritis in children

October 22, 2015
Medical Communications, Research and Development NICE, arthritis, jia

 UK Healthcare guidance body NICE has today published final draft guidance recommending four drugs for the treatment of juvenile ideopathic …

News
bmss_orencia_was_recommended_in_draft_guidance

NICE recommends four treatments for arthritis in children

October 22, 2015
Medical Communications, Research and Development NICE, arthritis, jia

 UK Healthcare guidance body NICE has today published final draft guidance recommending four drugs for the treatment of juvenile ideopathic …

News
novartissunlight_copy

Novartis’s secukinumab meets Phase 3 goals

October 1, 2015
Research and Development Novartis, Secukinumab, arthritis

Novartis has announced that its secukinumab medication for treatment of psoriatic arthritis (PsA), met its primary endpoint in the pivotal …

News

Humira biosimilar released in India

December 18, 2014
Research and Development, Sales and Marketing Humira, India, Zydus Cadila, anti-inflammatory, arthritis, bioscience

Indian firm Zydus Cadila has launched the first biosimilar of AbbVie’s anti-inflammatory medicine Humira, the world’s biggest-selling drug. Used as …

News
Janssen image

NICE U-turn over Janssen arthritis drug

December 9, 2014
Sales and Marketing Janssen, NHS, NICE, Stelara, arthritis, ustekinumab

NICE has reversed its decision on Janssen’s Stelara and is now recommending the active psoriatic arthritis drug. The pricing watchdog …

News
Stelara image

Stelara hit by final NICE rejection

March 28, 2014
Sales and Marketing Janssen, NICE, UK, arthritis, psoriatic, stelar

In final draft guidance released today NICE says it cannot recommend Janssen’s psoriatic arthritis drug Stelara. Specifically, the pricing watchdog …

News
Sanofi image

Sanofi and UCB launch new partnership

March 11, 2014
Research and Development, Sales and Marketing Sanofi, UCB, arthritis, autoimmune, partnership

Sanofi and UCB have announced a new partnership that will see the companies research and develop new medicines together. Specifically, …

News
Vimovo image

AstraZeneca sells arthritis drug for $35 million

November 20, 2013
Sales and Marketing AstraZeneca, RA, arthritis, horizon, vimovo

AstraZeneca has sold rights to its arthritis treatment Vimovo to speciality pharma firm Horizon Pharma for $35 million.  AZ retains …

News

New prescribing powers for UK physios and podiatrists

August 20, 2013
Medical Communications, Sales and Marketing Chartered Society of Physiotherapy, College of Podiatry, Norman Lamb, arthritis

News
Remicade image

Remicade copies set for European entry

July 1, 2013
Sales and Marketing CHMP, Hospira, Janssen, Remicade, arthritis, biosimilar

Janssen’s Remicade could soon come under generic pressure after a landmark recommendation by the CHMP. South Korean biotech Celltrion and …

News
RoActemra image

Roche’s RoActemra beats Humira in arthritis study

March 5, 2012
Research and Development, Sales and Marketing Humira, RA, RoActemra, Roche, arthritis

Roche’s rheumatoid arthritis drug RoActemra has beaten Abbott’s Humira in a head-to-head study. The Phase IV trial showed that RoActemra …

News

Late stage trial boost for Pfizer’s arthritis drug tasocitinib

November 8, 2010
JAK inhibitors, Pfizer, arthritis, tasocitinib

Pfizer’s rheumatoid arthritis treatment tasocitinib has met its two of its three primary endpoints in a phase III trial. Primary …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024